Shuo Qie

Prof. Shuo Qie

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2016 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
SQShuo Qie
Shuo Qie
JDJ. Alan Diehl
J. Alan Diehl

17 September 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
VGVictoria J. Gennaro
Victoria J. Gennaro
TSTimothy J. Stanek
Timothy J. Stanek
APAmy R. Peck
Amy R. Peck
YSYunguang Sun
Yunguang Sun
FWFeng Wang
Feng Wang
SMSteven B. McMahon
Steven B. McMahon
Significance: The deubiquitylase USP22 is frequently overexpressed in cancer and contributes to tumorigenesis by driving cell cycle progression. Current models define USP22 as functional mediator of gene regulation and chromatin modification, working within the SAGA transcriptional cofactor complex. Here we report a catalytic role for USP22 distinct from its well-characterized transcription regulatory capacity. USP22 directly stabilizes the essential G1-cyclin, CCND1, protecting it from proteasome-mediated degradation via deubiquitylation. Our findings reveal a pathway that regulates CCND1, while also raising the possibility that simulteously targeting USP22 may allow the use of less toxic doses of the new wave of cancer therapies that target the cyclin/CDK complex. Finally, these results provide a mechanistic explanation for the effects of USP22 in cancer cell cycle control.

21 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SQShuo Qie
Shuo Qie
AYAkihiro Yoshida
Akihiro Yoshida
SPStuart Parnham
Stuart Parnham
NONatalia Oleinik
Natalia Oleinik
GBGyda C. Beeson
Gyda C. Beeson
JDJ. Alan Diehl
J. Alan Diehl
The dysregulation of Fbxo4-cyclin D1 axis occurs at high frequency in esophageal squamous cell carcinoma (ESCC), where it promotes ESCC development and progression. However, defining a therapeutic vulnerability that results from this dysregulation has remained elusive. Here we demonstrate that Rb and mTORC1 contribute to Gln-addiction upon the dysregulation of the Fbxo4-cyclin D1 axis, which leads to the reprogramming of cellular metabolism. This reprogramming is characterized by reduced energy production and increased sensitivity of ESCC cells to combined treatment with CB-839 (glutaminase 1 inhibitor) plus metformin/phenformin. Of additional importance, this combined treatment has potent efficacy in ESCC cells with acquired resistance to CDK4/6 inhibitors in vitro and in xenograft tumors. Our findings reveal a molecular basis for cancer therapy through targeting glutaminolysis and mitochondrial respiration in ESCC with dysregulated Fbxo4-cyclin D1 axis as well as cancers resistant to CDK4/6 inhibitors.

2 May 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SQShuo Qie
Shuo Qie
NSNianli Sang
Nianli Sang
Stanniocalcin 2 (STC2) is a glycoprotein which is expressed in a broad spectrum of tumour cells and tumour tissues derived from human breast, colorectum, stomach, esophagus, prostate, kidney, liver, bone, ovary, lung and so forth. The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation. Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis. Importantly, STC2 also promotes the development of acquired resistance to chemo- and radio- therapies. In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response. Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients’ prognosis, highlighting its potential as a biomarker and a therapeutic target. This review focuses on discussing the regulation, biological functions and clinical importance of STC2 in human cancers. Future perspectives in this field will also be discussed.

1 May 2008 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
PDF file
JWJun-Yan Wang
Jun-Yan Wang
TSTao Sun
Tao Sun
XZXiu-Lan Zhao
Xiu-Lan Zhao
SZShi-Wu Zhang
Shi-Wu Zhang
QGQiang Gu
Qiang Gu
BSBao-Cun Sun
Bao-Cun Sun
Ovarian cancer is a silent killer, and shows early extensive tumor invasion and peritoneal metastasis. The microcirculation of most tumors includes cooperation of pre-existing vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid angiogenesis, and vasculogenic mimicry (VM). VM is critical for a tumor blood supply and is asscociated with aggressive features and metastasis. Our studies highlight the plasticity of aggressive human ovarian carcinoma cells and call into question the underlying significance of their ability to form VM in vitro induced by VEGF-a. These studies also show their clinicalpathological features of the cancers with human Paraffin-embedded tumor tissue samples. Results show that the process: VEGF-a→EphA2→MMPs→VM is the main pathway for VM formation and VEGF-a appears to play an important role in the formation of VM based on our in vitro assays and clinical immunohistochemical analyses. VM-targeting strategies for ovarian cancer include anti-VEGF-a treatment, knocking down the EphA2 gene and using antibodies against human MMPs if the tumor is VM positive. This strategy may be of significant value in laying the foundation for a more explicit anti-tumor angiogenesis therapy.

3 October 2013 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SQShuo Qie
Shuo Qie
CCClarissa Chu
Clarissa Chu
WLWeihua Li
Weihua Li
CWChenguang Wang
Chenguang Wang
NSNianli Sang
Nianli Sang